OncoMatch/Clinical Trials/NCT07162506
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Is NCT07162506 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Chemotherapy and Immunotherapy for esophageal cancer.
Treatment: Chemotherapy · Immunotherapy — This is a multi-center, Phase II clinical study aiming to evaluate the efficacy, safety, and organ preservation feasibility of definitive concurrent chemoradiotherapy versus surgery in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC) who achieve clinical complete response/partial response (cCR/PR) after neoadjuvant chemo-immunotherapy. A total of 120 eligible subjects will be enrolled. Patients with cCR/PR after 2-3 cycles of neoadjuvant chemo-immunotherapy will be grouped based on personal willing: the control group (n=60) will receive radical esophagectomy + mediastinal lymph node dissection; the experimental group (n=60) will receive definitive concurrent chemoradiotherapy (radiotherapy: 50.4 Gy/28f; chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles). All the patients will receive camrelizumab maintenance therapy (200mg q21d) up to 1 year.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage II, III, IVA (other)
clinically staged as Stage II - IVa (cT1N1-3M0, cT2-4aN0-3M0 before treatment; 8th AJCC)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy combined with anti-PD-1 or anti-PD-L1 monoclonal antibody — neoadjuvant
achieve cCR/PR after 2-3 cycles of platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies
Cannot have received: surgery for esophageal cancer
Surgery for esophageal cancer
Cannot have received: radiotherapy
Radiotherapy
Cannot have received: targeted therapy
targeted therapy
Lab requirements
Blood counts
ANC ≥ 1.5×10^9/L; platelets ≥ 80×10^9/L; hemoglobin ≥ 9g/dL; serum albumin ≥ 2.8g/dL
Kidney function
Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60mL/min
Liver function
Total bilirubin ≤ 1.5 × ULN, ALT, AST and/or ALP ≤ 2.5 × ULN
The function of major organs meets the following requirements: ... Absolute neutrophil count (ANC) ≥ 1.5×10^9/L; Platelets ≥ 80×10^9/L; Hemoglobin ≥ 9g/dL; Serum albumin ≥ 2.8g/dL; Total bilirubin ≤ 1.5 × ULN, ALT, AST and/or ALP ≤ 2.5 × ULN; Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60mL/min; INR and APTT ≤ 1.5× ULN (subjects on stable doses of anticoagulation therapy, such as low molecular weight heparin or warfarin, and with INR within the expected therapeutic range of the anticoagulant can be screened)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07162506 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgery for esophageal cancer, radiotherapy, targeted therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage II or III or IVA is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages